The company is advancing Radiprodil in multiple rare genetic epilepsies and neurodevelopmental disorders, with ongoing clinical trials.
Organizations Involved
Angelini Pharma, Blackstone Life Sciences
Founders
Bruce Leuchter, MD
Company Description
Grin Therapeutics, Inc. is a leader in the development of therapies to treat serious neurodevelopmental disorders, advancing Radiprodil, a targeted, selective, and potent negative allosteric modulator of the GluN2B subunit of the NMDA receptor.